UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) January 28, 2014

 

 

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

 

 

New Jersey

(State or Other Jurisdiction of Incorporation)

 

001-4802   22-0760120
(Commission File Number)   (IRS Employer Identification No.)
1 Becton Drive, Franklin Lakes, New Jersey   07417-1880
(Address of Principal Executive Offices)   (Zip Code)

(201) 847-6800

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 28, 2014, the Board of Directors of Becton, Dickinson and Company (“BD”) elected Joseph Mercurio, age 50, as Vice President and Corporate Controller. Mr. Mercurio will serve as BD’s principal accounting officer. Christopher R. Reidy, BD’s Chief Financial Officer and Executive Vice President of Administration, was serving as BD’s principal accounting officer in addition to his role as BD’s principal financial officer. Mr. Mercurio previously served as Worldwide Controller of BD’s Medical Surgical Systems business unit from January 2007 through December 2011, as Assistant Controller of BD’s Medical segment from January 2012 through August 2012, and most recently as Worldwide Controller of BD’s Diabetes Care business unit.

Item 5.07. Submission of Matters to a Vote of Security Holders.

BD’s 2014 Annual Meeting of Shareholders (“Annual Meeting”) was held on January 28, 2014. The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting are as follows:

Item No. 1: All of the Board of Directors’ nominees for director were elected to serve for a term of one year and until their respective successors are elected and qualified, by the votes set forth in the table below:

 

Nominee

         For              Against          Abstain        Broker
Non-Votes
 

Basil L. Anderson

     147,324,181         660,875         432,962         19,545,481   

Henry P. Becton, Jr.

     146,488,051         1,570,733         359,472         19,545,481   

Catherine M. Burzik

     147,656,469         338,741         423,046         19,545,481   

Edward F. DeGraan

     146,816,247         1,182,388         419,621         19,545,481   

Vincent A. Forlenza

     144,314,055         3,381,201         723,000         19,545,481   

Claire M. Fraser

     147,489,521         524,159         404,576         19,545,481   

Christopher Jones

     147,570,485         432,474         415,297         19,545,481   

Marshall O. Larsen

     147,397,298         614,163         406,795         19,545,481   

Gary A. Mecklenburg

     147,572,413         439,973         405,870         19,545,481   

James F. Orr

     146,789,081         1,170,828         458,347         19,545,481   

Willard J. Overlock, Jr.

     146,761,684         1,233,923         422,649         19,545,481   

Rebecca W. Rimel

     147,363,881         613,834         440,541         19,545,481   

Bertram L. Scott

     146,335,694         1,610,565         471,997         19,545,481   

Alfred Sommer

     146,592,390         1,379,576         446,289         19,545,481   

Item No. 2: The appointment of Ernst & Young as BD’s independent registered public accounting firm for fiscal year 2014 was ratified by the shareholders by the votes set forth in the table below:

 

For

 

Against

 

Abstain

165,746,047   1,717,239   500,451

Item No. 3: The shareholders approved, on an advisory, non-binding basis, the compensation of BD’s named executive officers by the votes set forth in the table below:

 

For

 

Against

 

Abstain

 

Broker

Non-Votes

143,506,728   3,290,687   1,620,841   19,545,481

Item No. 4: The shareholders approved the material terms of performance goals under BD’s 2004 Employee and Director Equity-Based Compensation Plan by the votes set forth in the table below:

 

For

 

Against

 

Abstain

 

Broker

Non-Votes

138,859,520   8,935,602   623,134   19,545,481

Item No. 5: The shareholders approved the material terms of performance goals under BD’s Performance Incentive Plan by the votes set forth in the table below:

 

For

 

Against

 

Abstain

 

Broker

Non-Votes

144,457,179   3,281,792   679,285   19,545,481

Item No. 6: The shareholders rejected a shareholder proposal requesting the Board of Directors to take the steps necessary to adopt a policy providing for an independent Board Chair by the votes set forth in the table below:

 

For

 

Against

 

Abstain

 

Broker

Non-Votes

44,005,091

  103,174,825   1,238,310   19,545,481


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

BECTON, DICKINSON AND COMPANY

(Registrant)

By:  

/s/ Gary DeFazio

  Gary DeFazio
  Vice President and Corporate Secretary

Date: January 30, 2014